Search research articles
Contact Us
Filters
Showing results (271-280 of 348) with videos related to
Page
of 35
Sort By:
The New England Journal of Medicine
|
December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Cancer Immunology Research
|
November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Nature Communications
|
May 19, 2023
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
Xiangling Xiao, Jie Shi, Chuan He, et al.
Journal of Translational Autoimmunity
|
August 4, 2020
Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis
Stinne R Greisen, Tue W Kragstrup, Jesper Skovhus Thomsen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 8, 2026
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection
Masao Hashimoto, Tahseen H Nasti, Hyun-Tak Jin, et al.
Cancer Immunology Research
|
November 8, 2015
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A Reardon, Prafulla C Gokhale, Sarah R Klein, et al.
Science (New York, N.Y.)
|
March 11, 2017
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O Kamphorst, Andreas Wieland, Tahseen Nasti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
Journal for Immunotherapy of Cancer
|
June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016
Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Oncotarget
|
January 23, 2015
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, et al.
Page
of 35
Search research articles
Search
Showing results (271-280 of 348) with videos related to
Sort By:
Page
of 35
The New England Journal of Medicine
|
December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Cancer Immunology Research
|
November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Nature Communications
|
May 19, 2023
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
Xiangling Xiao, Jie Shi, Chuan He, et al.
Journal of Translational Autoimmunity
|
August 4, 2020
Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis
Stinne R Greisen, Tue W Kragstrup, Jesper Skovhus Thomsen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 8, 2026
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection
Masao Hashimoto, Tahseen H Nasti, Hyun-Tak Jin, et al.
Cancer Immunology Research
|
November 8, 2015
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A Reardon, Prafulla C Gokhale, Sarah R Klein, et al.
Science (New York, N.Y.)
|
March 11, 2017
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O Kamphorst, Andreas Wieland, Tahseen Nasti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
Journal for Immunotherapy of Cancer
|
June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016
Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Oncotarget
|
January 23, 2015
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, et al.
Page
of 35